Found: 116
Select item for more details and to access through your institution.
Proposed crystal structure of carbadox, C11H10N4O4.
- Published in:
- Powder Diffraction, 2024, v. 39, n. 2, p. 1, doi. 10.1017/S0885715624000083
- By:
- Publication type:
- Article
PDF-5+: a comprehensive Powder Diffraction File™ for materials characterization.
- Published in:
- Powder Diffraction, 2024, v. 39, n. 2, p. 1, doi. 10.1017/S0885715624000150
- By:
- Publication type:
- Article
Crystal structure of ractopamine hydrochloride, C18H24NO3Cl.
- Published in:
- Powder Diffraction, 2024, v. 39, n. 2, p. 1, doi. 10.1017/S0885715624000095
- By:
- Publication type:
- Article
Crystal structure of nicarbazin, (C13H10N4O5)(C6H8N2O).
- Published in:
- Powder Diffraction, 2024, v. 39, n. 2, p. 1, doi. 10.1017/S0885715624000125
- By:
- Publication type:
- Article
Crystal structure of indacaterol hydrogen maleate (C24H29N2O3)(HC4H2O4).
- Published in:
- Powder Diffraction, 2024, v. 39, n. 2, p. 1, doi. 10.1017/S0885715624000071
- By:
- Publication type:
- Article
Cynarine monohydrate from synchrotron powder X‐ray diffraction data.
- Published in:
- Acta Crystallographica Section C: Structural Chemistry, 2022, v. 78, n. 2, p. 101, doi. 10.1107/S2053229622000687
- By:
- Publication type:
- Article
Crystal structure of alectinib hydrochloride Type I, C<sub>30</sub>H<sub>35</sub>N<sub>4</sub>O<sub>2</sub>Cl.
- Published in:
- Powder Diffraction, 2024, v. 39, n. 3, p. 170, doi. 10.1017/S0885715624000204
- By:
- Publication type:
- Article
Crystal structure of valbenazine, C<sub>24</sub>H<sub>38</sub>N<sub>2</sub>O<sub>4</sub>.
- Published in:
- Powder Diffraction, 2024, v. 39, n. 3, p. 176, doi. 10.1017/S0885715624000198
- By:
- Publication type:
- Article
Powder X-ray diffraction of nintedanib esylate hemihydrate, (C<sub>31</sub>H<sub>33</sub>N<sub>5</sub>O<sub>4</sub>)(C<sub>2</sub>H<sub>5</sub>O<sub>3</sub>S)(H<sub>2</sub>O)<sub>0.5</sub>.
- Published in:
- Powder Diffraction, 2024, v. 39, n. 3, p. 159, doi. 10.1017/S0885715624000186
- By:
- Publication type:
- Article
Crystal structure of brimonidine hydrogen tartrate, (C<sub>11</sub>H<sub>11</sub>BrN<sub>5</sub>)(HC<sub>4</sub>H<sub>4</sub>O<sub>6</sub>).
- Published in:
- Powder Diffraction, 2024, v. 39, n. 3, p. 144, doi. 10.1017/S0885715624000174
- By:
- Publication type:
- Article
Crystal structure of anthraquinone-2-carboxylic acid, C<sub>15</sub>H<sub>8</sub>O<sub>4</sub>.
- Published in:
- Powder Diffraction, 2024, v. 39, n. 1, p. 29, doi. 10.1017/S0885715624000046
- By:
- Publication type:
- Article
Crystal structure of danofloxacin mesylate (C<sub>19</sub>H<sub>21</sub>FN<sub>3</sub>O<sub>3</sub>)(CH<sub>3</sub>O<sub>3</sub>S).
- Published in:
- Powder Diffraction, 2023, v. 38, n. 3, p. 194, doi. 10.1017/S0885715623000271
- By:
- Publication type:
- Article
Crystal structure of meglumine diatrizoate, (C<sub>7</sub>H<sub>18</sub>NO<sub>5</sub>)(C<sub>11</sub>H<sub>8</sub>I<sub>3</sub>N<sub>2</sub>O<sub>4</sub>).
- Published in:
- Powder Diffraction, 2023, v. 38, n. 3, p. 185, doi. 10.1017/S0885715623000180
- By:
- Publication type:
- Article
Crystal structure of encorafenib, C<sub>22</sub>H<sub>27</sub>ClFN<sub>7</sub>O<sub>4</sub>S.
- Published in:
- Powder Diffraction, 2023, v. 38, n. 2, p. 145, doi. 10.1017/S0885715623000118
- By:
- Publication type:
- Article
Crystal structure of besifloxacin hydrochloride, C<sub>19</sub>H<sub>22</sub>ClFN<sub>3</sub>O<sub>3</sub>Cl.
- Published in:
- Powder Diffraction, 2023, v. 38, n. 1, p. 43, doi. 10.1017/S0885715622000586
- By:
- Publication type:
- Article
Crystal structure of oxfendazole, C<sub>15</sub>H<sub>13</sub>N<sub>3</sub>O<sub>3</sub>S.
- Published in:
- Powder Diffraction, 2023, v. 38, n. 1, p. 37, doi. 10.1017/S0885715622000574
- By:
- Publication type:
- Article
Crystal structure of deracoxib, C<sub>17</sub>H<sub>14</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub>S.
- Published in:
- Powder Diffraction, 2023, v. 38, n. 1, p. 64, doi. 10.1017/S0885715622000525
- By:
- Publication type:
- Article
Crystal structure of butenafine hydrochloride, C<sub>23</sub>H<sub>28</sub>NCl.
- Published in:
- Powder Diffraction, 2023, v. 38, n. 1, p. 30, doi. 10.1017/S0885715622000562
- By:
- Publication type:
- Article
Crystal structure of toceranib, C<sub>22</sub>H<sub>25</sub>FN<sub>4</sub>O<sub>2</sub>.
- Published in:
- Powder Diffraction, 2023, v. 38, n. 1, p. 21, doi. 10.1017/S0885715622000513
- By:
- Publication type:
- Article
Crystal structure of elvitegravir Form II, C<sub>23</sub>H<sub>23</sub>ClFNO<sub>5</sub>.
- Published in:
- Powder Diffraction, 2023, v. 38, n. 1, p. 53, doi. 10.1017/S0885715622000501
- By:
- Publication type:
- Article
Crystal structure of oxibendazole, C<sub>12</sub>H<sub>15</sub>N<sub>3</sub>O<sub>3</sub>.
- Published in:
- Powder Diffraction, 2023, v. 38, n. 1, p. 15, doi. 10.1017/S0885715622000495
- By:
- Publication type:
- Article
Crystal structure of halofuginone hydrobromide, C<sub>16</sub>H<sub>18</sub>BrClN<sub>3</sub>O<sub>3</sub>Br.
- Published in:
- Powder Diffraction, 2023, v. 38, n. 1, p. 7, doi. 10.1017/S088571562200046X
- By:
- Publication type:
- Article
Crystal structure of vismodegib, C<sub>19</sub>H<sub>14</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>3</sub>S.
- Published in:
- Powder Diffraction, 2023, v. 38, n. 1, p. 1, doi. 10.1017/S0885715622000446
- By:
- Publication type:
- Article
Crystal structure of haloxon, C<sub>14</sub>H<sub>14</sub>C<sub>l3</sub>O<sub>6</sub>P.
- Published in:
- Powder Diffraction, 2022, v. 37, n. 4, p. 235, doi. 10.1017/S0885715622000422
- By:
- Publication type:
- Article
Crystal structure of diclazuril, C<sub>17</sub>H<sub>9</sub>Cl<sub>3</sub>N<sub>4</sub>O<sub>2</sub>.
- Published in:
- Powder Diffraction, 2022, v. 37, n. 4, p. 230, doi. 10.1017/S0885715622000410
- By:
- Publication type:
- Article
Crystal structure of baricitinib, C16H17N7O2S.
- Published in:
- Powder Diffraction, 2022, v. 37, n. 3, p. 150, doi. 10.1017/S088571562200015X
- By:
- Publication type:
- Article
Crystal structure of ponazuril, C<sub>18</sub>H<sub>14</sub>F<sub>3</sub>N<sub>3</sub>O<sub>6</sub>S.
- Published in:
- Powder Diffraction, 2022, v. 37, n. 4, p. 225, doi. 10.1017/S0885715622000409
- By:
- Publication type:
- Article
Crystal structure of aminopentamide hydrogen sulfate, (C<sub>19</sub>H<sub>25</sub>N<sub>2</sub>O)(HSO<sub>4</sub>).
- Published in:
- Powder Diffraction, 2022, v. 37, n. 4, p. 200, doi. 10.1017/S0885715622000343
- By:
- Publication type:
- Article
Crystal structure of fulvestrant hydrate (ethyl acetate), C32H47F5O3S(H2O)0.16(C4H8O2)0.025.
- Published in:
- Powder Diffraction, 2022, v. 37, n. 3, p. 157, doi. 10.1017/S0885715622000239
- By:
- Publication type:
- Article
Crystal structure of imepitoin, C<sub>13</sub>H<sub>14</sub>ClN<sub>3</sub>O<sub>2</sub>.
- Published in:
- Powder Diffraction, 2022, v. 37, n. 4, p. 206, doi. 10.1017/S0885715622000392
- By:
- Publication type:
- Article
Crystal structure of nequinate, C<sub>22</sub>H<sub>23</sub>NO<sub>4</sub>.
- Published in:
- Powder Diffraction, 2022, v. 37, n. 4, p. 211, doi. 10.1017/S0885715622000379
- By:
- Publication type:
- Article
Powder X-ray diffraction of altrenogest, C<sub>21</sub>H<sub>26</sub>O<sub>2</sub>.
- Published in:
- Powder Diffraction, 2022, v. 37, n. 4, p. 240, doi. 10.1017/S0885715622000331
- By:
- Publication type:
- Article
Crystal structure of merimepodib, C23H24N4O6.
- Published in:
- Powder Diffraction, 2022, v. 37, n. 3, p. 143, doi. 10.1017/S0885715622000148
- By:
- Publication type:
- Article
Crystal structure of a second polymorph of germacrone, C<sub>15</sub>H<sub>22</sub>O.
- Published in:
- Powder Diffraction, 2022, v. 37, n. 2, p. 98, doi. 10.1017/S0885715622000057
- By:
- Publication type:
- Article
Powder X-ray diffraction of daclatasvir dihydrochloride Form N-2 (Daklinza®), C<sub>40</sub>H<sub>52</sub>N<sub>8</sub>O<sub>6</sub>Cl<sub>2</sub>.
- Published in:
- Powder Diffraction, 2021, v. 36, n. 3, p. 208, doi. 10.1017/S0885715621000397
- By:
- Publication type:
- Article
Crystal structure of osimertinib mesylate Form B (Tagrisso), (C<sub>28</sub>H<sub>34</sub>N<sub>7</sub>O<sub>2</sub>)(CH<sub>3</sub>O<sub>3</sub>S).
- Published in:
- Powder Diffraction, 2021, v. 36, n. 4, p. 282, doi. 10.1017/S0885715621000555
- By:
- Publication type:
- Article
Crystal structure of brigatinib Form A (Alunbrig®), C<sub>29</sub>H<sub>39</sub>ClN<sub>7</sub>O<sub>2</sub>P.
- Published in:
- Powder Diffraction, 2021, v. 36, n. 4, p. 262, doi. 10.1017/S0885715621000518
- By:
- Publication type:
- Article
Crystal structure of ivermectin hemihydrate ethanolate, (C<sub>48</sub>H<sub>74</sub>O<sub>14</sub>)(H<sub>2</sub>O)<sub>0.5</sub>(C<sub>2</sub>H<sub>5</sub>OH)<sub>0.82</sub>.
- Published in:
- Powder Diffraction, 2021, v. 36, n. 4, p. 247, doi. 10.1017/S0885715621000488
- By:
- Publication type:
- Article
Powder X-ray diffraction of pazopanib hydrochloride Form 1, C<sub>21</sub>H<sub>24</sub>N<sub>7</sub>O<sub>2</sub>SCl.
- Published in:
- Powder Diffraction, 2021, v. 36, n. 3, p. 205, doi. 10.1017/S0885715621000282
- By:
- Publication type:
- Article
Crystal structure of palbociclib isethionate Form B, (C<sub>24</sub>H<sub>30</sub>N<sub>7</sub>O<sub>2</sub>)(C<sub>2</sub>H<sub>5</sub>O<sub>4</sub>S).
- Published in:
- Powder Diffraction, 2021, v. 36, n. 3, p. 196, doi. 10.1017/S0885715621000361
- By:
- Publication type:
- Article
Powder X-ray diffraction of varenicline hydrogen tartrate Form B (Chantix<sup>®</sup>), (C<sub>13</sub>H<sub>14</sub>N<sub>3</sub>)(HC<sub>4</sub>H<sub>4</sub>O<sub>6</sub>).
- Published in:
- Powder Diffraction, 2021, v. 36, n. 3, p. 202, doi. 10.1017/S088571562100035X
- By:
- Publication type:
- Article
Crystal structure of levocetirizine dihydrochloride Form I, C<sub>21</sub>H<sub>27</sub>ClN<sub>2</sub>O<sub>3</sub>Cl<sub>2</sub>.
- Published in:
- Powder Diffraction, 2021, v. 36, n. 3, p. 181, doi. 10.1017/S0885715621000245
- By:
- Publication type:
- Article
Crystal structure of tamsulosin hydrochloride, C<sub>20</sub>H<sub>29</sub>N<sub>2</sub>O<sub>5</sub>SCl.
- Published in:
- Powder Diffraction, 2021, v. 36, n. 2, p. 85, doi. 10.1017/S0885715621000129
- By:
- Publication type:
- Article
Crystal structure of pomalidomide Form I, C<sub>13</sub>H<sub>11</sub>N<sub>3</sub>O<sub>4</sub>.
- Published in:
- Powder Diffraction, 2021, v. 36, n. 2, p. 114, doi. 10.1017/S0885715621000087
- By:
- Publication type:
- Article
Crystal structure of edoxaban tosylate monohydrate Form I, (C<sub>24</sub>H<sub>31</sub>ClN<sub>7</sub>O<sub>4</sub>S)(C<sub>7</sub>H<sub>7</sub>O<sub>3</sub>S)(H<sub>2</sub>O).
- Published in:
- Powder Diffraction, 2021, v. 36, n. 2, p. 107, doi. 10.1017/S0885715621000117
- By:
- Publication type:
- Article
Crystal structure of eltrombopag olamine Form I, (C<sub>2</sub>H<sub>8</sub>NO)<sub>2</sub> (C<sub>25</sub>H<sub>20</sub>N<sub>4</sub>O<sub>4</sub>).
- Published in:
- Powder Diffraction, 2021, v. 36, n. 2, p. 100, doi. 10.1017/S0885715621000099
- By:
- Publication type:
- Article
Crystal structure of tofacitinib dihydrogen citrate (Xeljanz<sup>®</sup>), (C<sub>16</sub>H<sub>21</sub>N<sub>6</sub>O)(H<sub>2</sub>C<sub>6</sub>H<sub>5</sub>O<sub>7</sub>).
- Published in:
- Powder Diffraction, 2021, v. 36, n. 2, p. 92, doi. 10.1017/S0885715621000105
- By:
- Publication type:
- Article
Crystal structure of (E)-doxepin hydrochloride, C<sub>19</sub>H<sub>22</sub>NOCl.
- Published in:
- Powder Diffraction, 2021, v. 36, n. 1, p. 43, doi. 10.1017/S0885715621000063
- By:
- Publication type:
- Article
Crystal structure of tezacaftor Form A, C<sub>26</sub>H<sub>27</sub>F<sub>3</sub>N<sub>2</sub>O<sub>6</sub>.
- Published in:
- Powder Diffraction, 2021, v. 36, n. 1, p. 56, doi. 10.1017/S0885715621000051
- By:
- Publication type:
- Article
Crystal structure of pimecrolimus Form B, C<sub>43</sub>H<sub>68</sub>ClNO<sub>11</sub>.
- Published in:
- Powder Diffraction, 2021, v. 36, n. 1, p. 35, doi. 10.1017/S088571562100004X
- By:
- Publication type:
- Article